RealTime Dynamix™: Psoriatic Arthritis Q4

RealTime Dynamix: Psoriatic Arthritis Q4 is the fourth installment of the 2016 report series focusing on current and anticipated future trends in the PsA market. The Q4 report contains constant trended content, including current and future patient share, barriers to growth, industry contact rates, awareness and familiarity with products in development and sources of information

RealTime Dynamix™: Rheumatoid Arthritis Q4

RealTime Dynamix: Rheumatoid Arthritis Q4 is the fourth installment of the 2016 report series focusing on current and anticipated future trends in the RA treatment landscape. The Q4 report contains constant trended content, including current and future patient share, barriers to growth, industry contact rates, awareness and familiarity with products in development and sources of

RealTime Dynamix™: Psoriasis Q4

RealTime Dynamix: Psoriasis Q4 is the third report in a three-part 2016 series focusing on current and anticipated future trends in the PsO market. Report content includes current and future patient share, treatment satisfaction, industry contact rates, awareness and familiarity with products in development, sources of information about development compounds, statement agreements, line of therapy

RealTime Dynamix™: Multiple Sclerosis Q4

Don’t miss the Q4 2016 update of RealTime Dynamix: Multiple Sclerosis, the sixth edition in an on-going series. We highlight responses from 100 neurologists about the evolving treatment patterns for disease-modifying therapies in MS. Emphasis on market shifts resulting from the introduction of Glatopa, the first generic DMT to enter the market, early indicators of

RealTime Dynamix™: Hyperkalemia

Spherix Global Insights has been following the development of the hyperkalemia market since June 2015, in advance of the FDA approval of Veltassa (patiromer FOS), the first agent for hyperkalemia to be approved in 50 years. Veltassa was launched in the US in January 2016 and is expected to face competition from ZS-9, another novel potassium binder in development by ZS Pharma (acquired by AstraZeneca in 2015). ZS Pharma was dealt a blow on April 26, 2016 when, instead of being approved, was issued a Complete Response Letter.